PMID: 2510412Sep 1, 1989Paper

Arrhythmogenic effect of flecainide--treatment with i.v. magnesium

Zeitschrift für Kardiologie
R MletzkoB Lüderitz

Abstract

We report on a 46-year-old woman with ventricular tachycardia and ventricular fibrillation after starting antiarrhythmic drug therapy with flecainide. The flecainide acetate plasma levels were always in the normal range. A successful therapeutical intervention was induced with two i.v. applications of 1,000 mg magnesium glutamate. A persistent suppression of ventricular rhythm disturbance was accomplished by continuous i.v. application of 4 mg magnesium glutamate/min.

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.